Andrei Yudin

Forticell Bioscience, Inc. focuses on advanced regenerative medicine and stem cell therapy. The company was founded in 1991 and is headquartered in Englewood Cliffs, NJ.

Ascension Ventures LLC (Ascension Ventures) is a venture capital subsidiary of Ascension Health founded in 2001. The firm is headquartered in St. Louis, Missouri.

EGS Healthcare Capital Partners LLC (EGS Healthcare Capital Partners) is a private equity firm founded in 1999 by Frederic Greenberg and Terry C. Vance. The firm is headquartered in Rowayton, Connecticut.

Hadasit Medical Research Services & Development Ltd. operates as technology transfer company of Hadassah Medical Center in Jerusalem. It identifies, protects, nurtures and commercializes the discoveries made at Hadassah Medical Center. The company's product include Doxil, Periochip, Travelan, Granagard, and Insupad. The company was founded on December 7, 1986 and is headquartered in Jerusalem, Israel.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

LifeBond Ltd. engages in the development of medical devices designed to restore and repair tissues to reduce post-operative complications. The company was founded by Nir Mashkif, Orahn Preiss-Bloom and Ishay Attar in 2007 and is headquartered in Caesarea, Israel.

Hadasit Bio-Holdings Ltd. /Private Equity/ (Hadasit Bio-Holdings /Private Equity/) is a private equity division of Hadasit Bio-Holdings Ltd. founded in 2005. The firm is headquartered in Jerusalem, Israel.

Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada.

Bio-MarCare Technologies Ltd. develops diagnostic kits based on novel biomarkers for early cancer identification, monitoring and assistance. Its product mCRC-Strat is a personalized medicine assay predicting responsiveness to anti EGFR therapy and Colon-MarCarePlex is a molecular assay (qRT-PCR) comprising a panel of RNA markers that can detect the advanced adenoma polyps as well as early stage colorectal cancer. The company was founded by Beatrice Uziely and Rachel Bar-Shavit in 2002 and is headquartered in Jerusalem, Israel.

Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada.

Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.

Bedside Clinical Systems, Inc. develops Responses to Illness Severity Quantification (RISQ) framework severity of illness clinical decision support for frontline healthcare professionals, hospital administrators and quality managers. It provides BedsidePEWS, that uses the RISQ framework to empower frontline clinicians who care for hospitalized children. The company was founded by Christopher Parshuram in March 2011 and is headquartered in Toronto, Canada.

Clinical Trials Ontario operates as a research and development company for various diseases. The company was founded in 2012 and is headquartered in Toronto, Canada.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.

Triphase Accelerator Corp. develops oncology drug therapeutics. It engages in accelerating oncology products from pre-investigational new drug (pre-IND) to Phase I/Phase II POC. The firm?s product includes Marizomib which is used in cancer treatment. The company is headquartered in Toronto, Canada.

QD Solar, Inc. develops photovoltaic cells using colloidal quantum dot technology in Canada. Its quantum dot technology combines silicon solar cells with infrared solar cells in a hybrid architecture to harvest more of the solar spectrum than silicon alone. The company was founded by Sjoerd Hoogland and Edward Hartley Sargent in 2014 and is headquartered in Toronto, Canada.

Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA.

Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA.

Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety.

Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation.